Navigation Links
Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference
Date:10/1/2009

FRANKLIN, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the 4th Annual JMP Securities Healthcare Conference on Tuesday, October 6, 2009 at 1pm ET. The presentation will occur live and will be held at The New York Palace Hotel in New York, NY.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

www.echotx.com

    For More Information:
    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (508)-530-0329

SOURCE Echo Therapeutics, Inc.


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Ungarn, February 12, 2016 /PRNewswire/ ... Medizintechnikunternehmen, das sich auf den ungedeckten medizinischen ... heute positive Ergebnisse seines klinischen Forschungsprogramms bekannt. ... Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen Funktionen ... Indiso ltd , ein Medizintechnikunternehmen, das sich ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed ... 39 states and Washington, D.C. as ... move that was commended by shareholder advocacy organization As You ... As You Sow. "Many people hold on to unneeded drugs ... can have tragic consequences." --> Conrad MacKerron ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been reported about the fitness ... access to health and wellness resources most Americans could ever dream of having at ... a schedule as frenetic as the U.S. President. , In honor of President’s ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Yisrayl Hawkins, Pastor ... article this week that uncovers what he says are the real facts surrounding all ... the Bible from parents and Sunday school teachers, and Yisrayl says there is more ...
(Date:2/12/2016)... ... February 12, 2016 , ... Planet Future ... new cartoon style themes are great for showcasing pictures, videos as well as text ... titles like introductions, lower thirds, transitions and a beautiful frame overlay. Pixel Film Studios ...
(Date:2/12/2016)... ... ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of the ... licensed under Dignity Health Arizona General Hospital , which opened last year in ... our new freestanding emergency room delivers the highest quality care to Mesa and the ...
Breaking Medicine News(10 mins):